Pacira Pharmaceuticals
VC Fund
San Diego, United States
Pacira Pharmaceuticals is a VC fund in San Diego focused on Biotechnology and Medical. Pacira Pharmaceuticals Inc. operates as a pharmaceutical company which engages in the development and manufacturing of injectable pharmaceutical products. Pacira Pharmaceuticals Inc. was formerly known as DepoTech Corp. was formerly as SkyePharma Inc. and changed its name to Pacira Pharmaceuticals Inc. in June, 2007. The company was founded in 1989and is based in San Diego, California. Pacira Pharmaceuticals Inc. operates as a subsidiary of Pacira, Inc.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 82%
Last updated:
For AI agents: llms.txt
Industries Pacira Pharmaceuticals invests in
Stages Pacira Pharmaceuticals invests in
Countries Pacira Pharmaceuticals invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Investment Focus
Industry
- Biotechnology 6 (55%)
- Medical 4 (36%)
- Health Care 3 (27%)
- Pharmaceutical 3 (27%)
- Genetics 1 (9%)
Stage
- Convertible Note 3 (27%)
- Series A 2 (18%)
- Seed 1 (9%)
- Series B 1 (9%)
- Funding Round 1 (9%)
Country
- United States 5 (45%)
- Germany 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Charles A. Reinhart III
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Dennis McLoughlin
Area Sales Director
|
Area Sales Director | Total investments: 1 | Find email | |
Paul R. Ellwood
Vice President, Human Resources
|
Vice President, Human Resources | Total investments: 0 | Find email | |
Donald C. Manning
Chief Medical Officer
|
Chief Medical Officer | Total investments: 0 | Find email | |
John Bartolick
Vice President IT
|
Vice President IT | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improvethe lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life. | $13M / Convertible Note / Feb 08, 2023 | ||
| CarthroniX is a pharmaceutical company that offers small molecule based therapy, wound healing, skin regeneration, and novel solutions. | $2.3M / Convertible Note / Apr 11, 2022 | ||
| Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improvethe lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life. | $13M / Series B / Mar 23, 2022 | ||
| Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases | $10.5M / Series A / Jan 07, 2022 | ||
| CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity. With chemogenetics, target neuronal populations are modified using gene therapy to express a tunable ligand-gated ion channel. These ligand-gated ion channels are engineered to be highly responsive to a specific proprietary small molecule but are otherwiseinactive. The interaction of the small molecule and engineered receptor allows for exquisite, dose-dependent control of the neurons to generate the therapeutic effect. | $28M / Venture - Series Unknown / Dec 02, 2021 | ||
| Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improvethe lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life. | $3M / Convertible Note / Apr 20, 2021 | ||
| GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse. | $6.6M / Series A / Feb 15, 2021 | ||
| GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse. | $3.1M / Debt Financing / Feb 15, 2021 | ||
| GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse. | $3.3M / Convertible Note / Feb 15, 2021 | ||
| AVALON.AI is a Healthcare company that features an AI solution for real-time analysis using various data sources to generate a heat map of the areas that are affected by the pandemics like Coronavirus from a global to a hyper-local level. Its enterprise solution supports all business, government, educational, and healthcare silos. | $1.5M / Seed / Aug 28, 2020 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Pacira Pharmaceuticals invest in?
Pacira Pharmaceuticals invests primarily in Biotechnology, Medical and Health Care startups, most often at Convertible Note and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Pacira Pharmaceuticals?
Public channels for Pacira Pharmaceuticals include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pacira Pharmaceuticals?
The team at Pacira Pharmaceuticals includes Charles A. Reinhart III (Chief Financial Officer), Dennis McLoughlin (Area Sales Director) and Paul R. Ellwood (Vice President, Human Resources), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
